Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020;12(4):410-421.
doi: 10.1007/s40506-020-00236-3. Epub 2020 Oct 29.

Hantavirus Infections-Treatment and Prevention

Kalpa Dheerasekara  1 , Saranga Sumathipala  2 , Rohitha Muthugala  1
Affiliations
Review

Hantavirus Infections-Treatment and Prevention

Kalpa Dheerasekara et al. Curr Treat Options Infect Dis. 2020.

Abstract

Purpose of review: Hantavirus infection is an emerging zoonosis and there are two main clinical presentations, hemorrhagic fever with renal syndrome (HFRS) and Hantavirus pulmonary syndrome (HPS). Although Hantavirus infections have a worldwide distribution with a high mortality rate, a safe and effective vaccine or an antiviral drug against the Hantavirus disease is yet to be available. This review summarizes all the efforts undertaken to develop medical countermeasures in vitro, in vivo, and human clinical trials against Hantavirus infections.

Recent findings: Multiple antivirals are shown to be effective with limited evidence and recent studies on immunotherapy were not very conclusive. There are multiple vaccine candidates with evidence of conferring long protective immunity against Hantaviruses. Some of these had been already trialed on humans.

Summary: At present, severe HPS or HFRS case management is purely based on supportive treatments, often in an intensive care unit. Rodent control and public health education and promotion play a major role in preventing Hantavirus infection.

Keywords: Antiviral therapy; HFRS; HPS; Hantavirus infections; Hantavirus vaccines; Ribavirin.

PubMed Disclaimer

References

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance
    1. Schmaljohn CS. Vaccines for Hantaviruses: progress and issues. Expert Rev Vaccines. 2012;11(5):511–513. - PubMed
    1. Maes P, Clement J, Van Ranst M. Recent approaches in hantavirus vaccine development. Expert Rev Vaccines. 2009;8(1):67–76. - PubMed
    1. Schmauohn CS, Schmauohn AL, Dalrymple JM. Hantaan virus MRNA: coding strategy, nucleotide sequence, and gene order. Virology. 1987;157(1):31–39. - PubMed
    1. Schmaljohn CS, Jennings GB, Hay J, Dalrymple JM. Coding strategy of the S genome segment of Hantaan virus. Virology. 1986;155(2):633–643. - PubMed
    1. Schmaljohn CS. Nucleotide sequence of the L genome segment of hantaan virus. Nucleic Acids Res. 1990;18(22):6728. - PMC - PubMed

LinkOut - more resources